Overview and recent advances in the purification and isolation of therapeutic oligonucleotides

Abe, Aljaž (avtor), Časar, Zdenko (avtor)

Therapeutic oligonucleotides are a novel chemical modality with unique characteristics that offer significant therapeutic potential. With the latest surge in development, they are paving the way to the market at a rapid pace. To support that, scalable and economically sustainable oligonucleotide production is required. The upstream part exploits the well-studied phosphoramidite chemistry, known from the 1960s, using automated synthesis on a solid support. On the other hand, the downstream processing, which consists of purification and isolation steps, has stayed in the shadow of the more thoroughly studied synthesis, even though it is often regarded as the bottleneck of therapeutic oligonucleotide production. Therefore, this review aims to highlight the most important traditional purification and isolation approaches for the production of therapeutic oligonucleotides that ensure product quality, yields, scale, and cost-efficiency as well as newly emerging separation technologies that could become relevant in the future.

• Jezik: Angleški jezik
• Ključne besede: biopolymers, purification, preparative chromatography, diazoniumultrafiltration, oligonucleotides, continuous chromatography, ultrafiltration, freeze-drying, chromatography, genetics, impurities
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2025
• Št. strani: Str. 15-33
• Številčenje: Vol. 29, iss. 1
• PID: 20.500.12556/RUL-166641
• UDK: 615
• ISSN pri članku: 1083-6160
• DOI: 10.1021/acs.oprd.4c00382
• COBISS.SI-ID: 222989059
• Datum objave v RUL: 20.01.2025

Gradivo je del revije

• Naslov: Organic process research & development
• Skrajšan naslov: Org. process res. dev.
• Založnik: American Chemical Society
• ISSN: 1083-6160
• COBISS.SI-ID: 3490842

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Projekti

• Financer: Drugi - Drug financer ali več financerjev
• Program financ.: Lek d.d., Sandoz Company